Doehn Christian, Kausch Ingo, Böhmer Torsten, Sommerauer Martin, Jocham Dieter
University of Lübeck Medical School, Department of Urology, Ratzeburger Allee 160, 23538 Lübeck, Germany.
Curr Opin Mol Ther. 2007 Apr;9(2):183-9.
Therion Biologics Corp is developing PROSTVAC-VF-TRICOM, a prime-boost vaccine regimen that consists of a priming injection with a recombinant attenuated vaccinia virus expressing PSA and TRICOM (the company's proprietary triad of costimulatory molecules: ICAM-1, B7.1 and lymphocyte function-associated antigen-3), and a booster injection with a fowlpox virus expressing the same combination, for the potential treatment of prostate cancer. Phase II clinical trials are underway.
赛立昂生物公司正在研发PROSTVAC-VF-TRICOM，这是一种初免-加强疫苗方案，包括一次初免注射，使用表达前列腺特异性抗原（PSA）和TRICOM（该公司专有的共刺激分子三联体：细胞间黏附分子-1、B7.1和淋巴细胞功能相关抗原-3）的重组减毒痘苗病毒，以及一次加强注射，使用表达相同组合的鸡痘病毒，用于前列腺癌的潜在治疗。II期临床试验正在进行中。
